New drug combo shows promise for untreatable liver cancer

NCT ID NCT05546879

Ongoing Disease control Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior systemic treatment will receive the combination. The main goal is to check for side effects, while also tracking how well the tumors shrink and how long patients live.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Show contact details

Locations

12 Hôpital St Joseph

Marseille, France
AP-HP Beaujon

Paris, France
AP-HP St Antoine

Paris, France
CHU Angers

Angers, France
CHU Nantes

Nantes, France
CHU Reims

Reims, France
CHU Toulouse

Toulouse, France
CHU de GRENOBLE ALPES

Grenoble, Alpes, 38043, France
Hôpital Haut Lêveque

Bordeaux, France